PDCD1 and neoplasm: In a preclinical study conducted on MC38 colon tumor-bearing mice, the combination of avasimibe and an anti-PD-1 antibody displayed superior efficacy in controlling tumor progression compared to either monotherapy, resulting in a significant anti-tumor effect [172].